SCHEMBL544346

SCHEMBL544346

Clc1ccc(Br)cc1OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.54
MAOB P27338 1/20 0.53
CCR5 P51681 5/20 0.52
MGAM O43451 1/20 0.50
GAA P10253 1/20 0.50
SI P14410 1/20 0.50
MGAM2 Q2M2H8 1/20 0.50
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 2/20 0.49
USP28 Q96RU2 1/20 0.49
USP25 Q9UHP3 1/20 0.49
PTGER1 P34995 2/20 0.48
LRRK2 Q5S007 1/20 0.48
HTT P42858 2/20 0.48
MRGPRX4 Q96LA9 1/20 0.48
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
MITF O75030 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2767847 0.86 RAB9A (0.56) SLC6A4MAOBCCR5RAB9AALDH1A1
SCHEMBL31644088 0.84 SLC6A4 (0.66) SLC6A4MAOBCCR5RAB9AALDH1A1
SCHEMBL368071 0.84 SLC6A4 (0.66) SLC6A4MAOBCCR5RAB9AALDH1A1
SCHEMBL17589345 0.82 MRGPRX4 (0.66) SLC6A4MGAMGAASIMGAM2
SCHEMBL4434864 0.82 SLC6A4 (0.56) SLC6A4MAOBCCR5RAB9AALDH1A1
SCHEMBL20482580 0.81 MGAM (0.49) CCR5MGAMGAASIMGAM2
SCHEMBL190649 0.81 MAOB (0.51) SLC6A4MAOBCCR5RAB9AALDH1A1
SCHEMBL21327244 0.81 ALOX5 (0.58) MAOBMGAMGAASIMGAM2
SCHEMBL2707432 0.81 MRGPRX4 (0.52) MGAMGAASIMGAM2RAB9A
SCHEMBL29809154 0.80 CCR5 (0.51) SLC6A4MAOBCCR5RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11986471-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-05-21 US disclosed
US-20230060499-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-03-02 US disclosed
US-11077101-B1 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2021-08-03 US disclosed
EP-3492467-A1 ISOQUINOLINONE COMPOUND AND USE THEREOF IN PREPARATION OF ANTIVIRAL DRUGS Ginkgo Pharma Co., Ltd. (CN) 2019-06-05 EP disclosed
EP-2439193-B1 Derivatives of 5,6-bisaryl-2-pyridine-carboxamide, preparation and use thereof in therapeutics as antagonists of urotensin II receptors SANOFI SA (FR) 2014-04-23 EP disclosed
US-8552201-B2 5, 6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists SANOFI (FR) 2013-10-08 US disclosed
CN-101511789-B 5, 6-bisaryl-2-pyridine-carboxamide derivatives, their preparation and their use in therapy as urotensin II receptor antagonists SANOFI AVENTIS 2012-05-23 CN disclosed
US-20120108611-A1 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS SANOFI-AVENTIS 2012-05-03 US disclosed
EP-2059508-B1 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS SANOFI SA (FR) 2012-04-11 EP disclosed
US-8110579-B2 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists SANOFI-AVENTIS (FR) 2012-02-07 US disclosed
US-20090318473-A1 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS SANOFI AVENTIS 2009-12-24 US disclosed
CN-101511789-A 5, 6-bisaryl-2-pyridine-carboxamide derivatives, their preparation and their use in therapy as urotensin II receptor antagonists SANOFI AVENTIS (FR) 2009-08-19 CN disclosed
EP-2059508-A1 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS Sanofi-Aventis (FR) 2009-05-20 EP disclosed
EP-1841425-A4 PHENYL-SUBSTITUTED PYRROLIDONES IRM LLC A DELWARE LTD LIABILIT (BM) 2009-02-18 EP disclosed
US-20080287516-A1 Phenyl-Substituted Pyrrolidones IRM LLC (BM) 2008-11-20 US disclosed
WO-2008020124-A1 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2008-02-21 WO disclosed
CN-101115481-A Phenyl-substituted pyrrolidones IRM LLC (BM) 2008-01-30 CN disclosed
CN-101111246-A Synthesis of aryl pyrrolidones IRM LLC (BM) 2008-01-23 CN disclosed
EP-1841425-A2 PHENYL-SUBSTITUTED PYRROLIDONES IRM LLC A Delware Limited Liability Company (BM) 2007-10-10 EP disclosed
WO-2006081554-A2 PHENYL-SUBSTITUTED PYRROLIDONES IRM LLC (BM) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318473-A1 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS UTS2R, PLAUR, NTSR2 SLC6A4 2954/4885MAOB 887/4885CCR5 498/4885
US-11986471-B2 Compounds and methods of use XDH, F12, LPXN SLC6A4 630/4885MAOB 290/4885CCR5 159/4885
US-11077101-B1 Compounds and methods of use XDH, F12, LPXN SLC6A4 630/4885MAOB 290/4885CCR5 159/4885
US-20120108611-A1 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS UTS2R, PLAUR, NTSR2 SLC6A4 2954/4885MAOB 887/4885CCR5 498/4885
US-20230060499-A1 COMPOUNDS AND METHODS OF USE XDH, F12, LPXN SLC6A4 630/4885MAOB 290/4885CCR5 159/4885
US-20080287516-A1 Phenyl-Substituted Pyrrolidones MALT1, FKBP5, PREP SLC6A4 1421/4885MAOB 666/4885CCR5 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.